Strategic Collaborations Via Nova’s focus on urgent viral disease therapies and its early-stage profile with modest revenue and a $5 million funding round make it an ideal candidate for strategic collaborations or licensing deals with larger pharma players. Business development opportunities include co-development arrangements, milestone-based licensing, or strategic research partnerships that de-risk and accelerate programs targeting influenza, rhinovirus, BK virus, and adenovirus. Their Berkeley location can facilitate rapid partner engagement through proximity to biotech networks and academic collaborations.

External R&D Outsourcing With a small team, external R&D partners will be essential; this creates clear opportunities for CROs, contract analytics, and regulatory consulting that can scale with programs. Propose services that dovetail with their current tech stack—secure e-signature, integrated trial management, ELN/LIMS, and data workflow solutions—to streamline collaboration and speed to milestones.

Growth Financing Readiness Funding in the multi-million range and near-zero revenue imply a growth-driven purchasing stance; vendors can offer cost-efficient, modular services such as pilot assay development, preclinical data packages, and milestone-based engagements that align with their funding cadence. Bundle offerings with grant support and flexible procurement terms to reduce upfront risk and demonstrate rapid value.

Bay Area Collaboration Edge Bay Area proximity offers access to top universities, incubators, and venture activity, which can fuel collaborations, talent access, and co-funded studies. Position opportunities around early-stage preclinical collaborations, joint grant applications, and on-site support for fast-paced project kickoff and ongoing partner management in a local ecosystem.

Antiviral Focus Opportunities Their antiviral focus creates demand for specialized virology services, including assay development, hit confirmation, lead optimization support, and preclinical data generation. Act as a partner for rapid, cost-effective experimentation and technical diligence, with scalable service models and potential pathways toward later-stage manufacturing partnerships.